

## Great Lakes NeuroTechnologies Appoints Director of Sales & Marketing, Global Business



**10 November 2021: Cleveland, OH – Great Lakes NeuroTechnologies (GLNT)** is pleased to appoint Bill Bauza to the position of Director of Sales & Marketing, Global Business. Bauza will be tasked with the discovery of movement disorder clinical research projects at the investigator, sponsor, & site level. With this appointment, GLNT continues to expand its global reach as a resource in the clinical research of movement disorders.

Speaking about Bauza’s appointment, Dustin Heldman, President and COO of GLNT, stated, “Bill comes to Great Lakes NeuroTechnologies with extensive experience in healthcare leadership in capacities at both the institution and commercial markets. Having been part of the research, as well as the launch of multiple pharmaceuticals and devices, Bill has the acumen to deliver the value-based resources that Great Lakes NeuroTechnologies has to offer.”

“I am excited to be joining the Great Lakes NeuroTechnologies team,” said Bauza. “Great Lakes NeuroTechnologies is the leader in this space and offers researchers and corporate sponsors alike, accurate & repeatable data with its wearable Kinesia devices for the objective monitoring of movement disorders.”

### About Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies [ <http://www.glneurotech.com> ] is committed to pioneering innovative biomed technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.

### About Kinesia™ Technology

GLNT commercialized Kinesia™ technology to provide wearable, objective and automated assessment of movement disorders such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. The technology is protected by 33 US and international patents shown at <https://www.glneurotech.com/patents/>.

### Media Relations

[media@glneurotech.com](mailto:media@glneurotech.com)  
216-361-5410

###